A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE003 (CAN) · Dr. Okafor
consented 2022-02-18
Adverse events
Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-03-16 (study day 10); relationship: not assessed
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-03-30 (study day 24); relationship: not assessed
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-04-29 (study day 54); relationship: N
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-07-18 (study day 134); relationship: not assessed
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-09-23 (study day 201); relationship: Y
Data queries
No data queries.